Abstract
Tuberculosis (TB) remains one of the most deadly infectious diseases in the world, killing about 2 million people per year, and mostly affecting the worlds poorest population. The length of current regimens for treatment of TB is long (6-9 months) with a high pill burden. Furthermore, one third of the world population is infected, though asymptomatically, with latent TB and is at risk of developing active TB disease during their lifetime. The current TB epidemic is fuelled by co-infection with HIV, the rise of multidrug-resistant strains, and the ability of the bacterium to become dormant in the lungs and to be reactivated in immunocompromised people. Despite medical advances over the last decades, including the genomic and proteomic revolution, TB still is a highly neglected disease. However, the search for new TB drugs is gaining momentum. Several efforts are underway to develop new drugs, within the academia, the pharmaceutical industry and as public private partnerships. This review will provide a chemical, biological and pharmacological overview of the six drug candidates currently in clinical development. Moxifloxacin (fluoroquinolone), TMC207 (diarylquinoline), PA-824 and OPC-67683 (nitroimidazoles), LL3858 (pyrrole) and SQ109 (ethambutol analogue) will be presented.
Keywords: Infectious disease, Mycobacterium tuberculosis, Moxifloxacin, TMC207, PA824, OPC67683, LL3858, SQ109
Current Bioactive Compounds
Title: New Anti-Tuberculosis Drugs in Clinical Development: An Overview
Volume: 5 Issue: 2
Author(s): Jerome Guillemont, Frederic Lieby-Muller, Nacer Lounis, Wendy Balemans, Anil Koul and Koen Andries
Affiliation:
Keywords: Infectious disease, Mycobacterium tuberculosis, Moxifloxacin, TMC207, PA824, OPC67683, LL3858, SQ109
Abstract: Tuberculosis (TB) remains one of the most deadly infectious diseases in the world, killing about 2 million people per year, and mostly affecting the worlds poorest population. The length of current regimens for treatment of TB is long (6-9 months) with a high pill burden. Furthermore, one third of the world population is infected, though asymptomatically, with latent TB and is at risk of developing active TB disease during their lifetime. The current TB epidemic is fuelled by co-infection with HIV, the rise of multidrug-resistant strains, and the ability of the bacterium to become dormant in the lungs and to be reactivated in immunocompromised people. Despite medical advances over the last decades, including the genomic and proteomic revolution, TB still is a highly neglected disease. However, the search for new TB drugs is gaining momentum. Several efforts are underway to develop new drugs, within the academia, the pharmaceutical industry and as public private partnerships. This review will provide a chemical, biological and pharmacological overview of the six drug candidates currently in clinical development. Moxifloxacin (fluoroquinolone), TMC207 (diarylquinoline), PA-824 and OPC-67683 (nitroimidazoles), LL3858 (pyrrole) and SQ109 (ethambutol analogue) will be presented.
Export Options
About this article
Cite this article as:
Guillemont Jerome, Lieby-Muller Frederic, Lounis Nacer, Balemans Wendy, Koul Anil and Andries Koen, New Anti-Tuberculosis Drugs in Clinical Development: An Overview, Current Bioactive Compounds 2009; 5 (2) . https://dx.doi.org/10.2174/157340709788451975
DOI https://dx.doi.org/10.2174/157340709788451975 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Anti Bacterial Therapy
Infectious Disorders - Drug Targets Antibiotic Sensitivity of Bacillus clausii Strains in Commercial Preparation
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Renal Phosphate Handling in Antiretroviral-naive HIV-Infected Patients
Infectious Disorders - Drug Targets Mycobacterium w Immunotherapy for Treating Pulmonary Tuberculosis - a Systematic Review
Current Pharmaceutical Design Anomalous Vascular Supply of Bronchial Circulation in Cystic Fibrosis Patients with Massive Hemoptysis
Current Respiratory Medicine Reviews Editorial (Thematic Issue: Biomarkers of Impaired Innate and Adaptive Immunity in Health and Disease)
Current Immunology Reviews (Discontinued) Anti-Inflammatory Effects of Antidepressants: Possibilities for Preventives Against Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Meet Our Editorial Board Member:
Current Organic Chemistry Editorial [(Poly)phenol Chemistry: Part II - Physicochemical Properties & Biological Implications (Guest Editor: Stefan Chassaing)]
Current Organic Chemistry Small Animal Models for Human Immunodeficiency Virus (HIV), Hepatitis B, and Tuberculosis: Proceedings of an NIAID Workshop
Current HIV Research Tailored Multi-Target Agents. Applications and Design Considerations
Current Pharmaceutical Design Multiple Myeloma or Brucellosis: A Case Report
Infectious Disorders - Drug Targets The Beneficial Role of Vitamin D in Human Immunodeficiency Virus Infection
Current HIV Research Leishmaniasis: History, Evolution of Treatment and the Need for New Drugs
Current Biotechnology MIF and the Genetic Basis of Macrophage Responsiveness
Current Immunology Reviews (Discontinued) Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Recent Patents on Proteases and Kinases as Anti-Infective Agents: A Review
Recent Patents on Anti-Infective Drug Discovery Short Antimicrobial Peptides
Recent Patents on Anti-Infective Drug Discovery Medicinal Chemistry of ATP Synthase: A Potential Drug Target of Dietary Polyphenols and Amphibian Antimicrobial Peptides
Current Medicinal Chemistry Synthesis and Antitubercular Evaluation on Novel 1-Ethyl-5-(hetero)aryl- 1,6-dihydropyrazine-2,3-dicarbonitriles and 3-Cyano-1-ethyl-5-(hetero) aryl-2(1H)-pyrazinones
Anti-Infective Agents